White Paper

Ensuring Access and Approval for Innovative Therapies in Scleroderma

Payer sentiments, outcomes, comorbidities, and more for innovative therapies treating scleroderma

Read more

This white paper discusses the strategy to create an integrated and innovative program capable of demonstrating the “value” of a therapy for scleroderma, as well as clinical utility and therapeutic novelty.


Chief Medical and Scientific Officer

Want to learn more about Worldwide Clinical Trials?